$2.11
-4.5%Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Wall Street analysts project that ACTU stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 21.00, with estimates ranging from a low of 21.00 to a high of 21.00.
The consensus 1-year price target stands at 21.00, with estimates ranging from a low of 21.00 to a high of 21.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.
Reasonable estimate spread indicates general agreement with normal forecast variance.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Declining expectations indicate headwinds—investigate whether temporary or structural issues.
Limited coverage may indicate reduced institutional interest or information availability.
Reasonable estimate spread indicates general agreement with normal forecast variance.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $1.50M and sold $1.62M worth of ACTU shares, resulting in $124K of net selling activity.
0
0.00
0
0.00
+0
+$0
0
0.00
280.0K
1.62M
-1.6M
-$1.62M
0
0.00
0
0.00
+0
+$0
214.3K
1.50M
0
0.00
+1.5M
+$1.50M
Kreis Leslie W.
Director, 10 Percent Owner:
$500K
Bios Equity Cof, Lp
Director, 10 Percent Owner:
$500K
Fletcher Aaron G.L.
Director, 10 Percent Owner:
$500K
Thomson Todd S
Director, 10 Percent Owner:
$1.62M
Slightly bearish with $124K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
Continue your ACTU research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.